UDM-001651
Cat. No.：YN322279
| 产品名称: | UDM-001651 |
| CAS No.: | 1477497-01-0 |
| Chemical Name: | |
| Synonyms: | 6-(4-((3-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole;GTPL10442;BDBM364746;US9862730, Example 205;compound 54 [PMID: 31246024];2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidaz |
| 分子量: | 513.56 |
| 分子式: | C28H23N3O5S |
| SMILES: | S1C(=NN2C1=NC(=C2[H])C1=C([H])C2C(=C([H])C(=C([H])C=2O1)OC([H])([H])[H])OC([H])([H])C1C([H])=C([H])C([H])=C(C=1[H])OC([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])OC([H])([H])[H] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | UDM-001651 是一种有效选择性的、口服生物可利用的蛋白酶激活受体 4(PAR4)拮抗剂 (IC50=4 nM；Kd=1.4 nM)。UDM-001651 在 γ-凝血酶诱导的富含血小板的血浆聚集测定 (γ-Thr PRP) 中显示抗血小板活性 (IC50=25 nM)。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
